We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Naltrexone

News List

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study Biotech Newswire
August 28, 2024
Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.
New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues Biotech Newswire
July 24, 2024
Currax Pharmaceuticals LLC announced the approval of additional manufacturing site for CONTRAVE®/MYSIMBA® in the European Union and European Union Economic Areas.
Pharmaceutical Treatments for Opioid Abuse May Benefit Teens drugs
September 18, 2019
Teens who misuse prescription or illicit opioids might benefit from the opioid treatment medications methadone, buprenorphine, and naltrexone...